- Home
- FHTX vs NFE Comparison
FHTX vs NFE Comparison
Compare FHTX & NFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FHTX | NFE |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Oil/Gas Transmission |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.2M | 324.4M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FHTX | NFE |
|---|---|---|
| Price | $4.89 | $0.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $11.50 | $7.70 |
| AVG Volume (30 Days) | 155.6K | ★ 19.2M |
| Earning Date | 03-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.32 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $30,909,000.00 | ★ $2,364,860,000.00 |
| Revenue This Year | $16.83 | N/A |
| Revenue Next Year | $15.06 | $89.10 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.75 | N/A |
| 52 Week Low | $2.94 | $0.68 |
| 52 Week High | $6.95 | $8.58 |
Technical Indicators
Market Signals| Indicator | FHTX | NFE |
|---|---|---|
| Relative Strength Index (RSI) | 40.15 | 27.20 |
| Support Level | $4.47 | N/A |
| Resistance Level | $5.85 | $1.38 |
| Average True Range (ATR) | 0.33 | 0.13 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 21.81 | 1.44 |
Price Performance
Historical ComparisonAbout FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About NFE New Fortress Energy Inc.
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.